Comparing visual function in Parkinson's patients and healthy individuals

"Characterization of Visual Problems in Patients With Parkinson's Disease and Application of an Oculomotor and/or Perceptual Therapy Program"

University of Valencia · NCT06032130

This study is testing how vision works in people with Parkinson's disease compared to healthy individuals to see if certain exercises can help improve or stabilize their visual problems.

Quick facts

Study typeObservational
Enrollment160 (estimated)
Ages30 Years to 100 Years
SexAll
SponsorUniversity of Valencia (other)
Locations1 site (Valencia)
Trial IDNCT06032130 on ClinicalTrials.gov

What this trial studies

This observational study aims to characterize the visual capabilities of patients with Parkinson's disease (PD) by comparing their visual function to that of healthy subjects. Non-invasive tests will be conducted to measure various aspects of visual acuity, eye movements, and quality of life. Following this, oculomotor or perceptual therapy exercises will be administered to assess potential improvements or stabilization of visual impairments in PD patients. The goal is to identify optometric solutions that may help slow down visual deterioration associated with PD.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with Parkinson's disease who do not have other neurodegenerative diseases or ocular pathologies.

Not a fit: Patients with significant ocular pathologies or other systemic illnesses that affect visual function may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide new therapeutic approaches to mitigate visual impairments in Parkinson's patients.

How similar studies have performed: While there is ongoing research into visual impairments in Parkinson's disease, this specific approach combining visual therapy with observational assessments is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Subjects without neurodegenerative diseases or systemic illnesses or ocular pathologies.
* Subjects not taking medication with visual side effects.
* Subjects able to perform the tests.
* Subjects of similar age and sex as their corresponding Parkinson's patient so that both samples are age and gender matched.
* Subjects diagnosed with Parkinson's disease.
* Parkinson's patients classified according to the Hoehn \& Yahr Scale.

Exclusion Criteria:

* Subjects with ocular pathologies (such as Glaucoma, Age-Related Macular Degeneration, Retinopathies, Corneal Opacifications, Senile Cataracts, Severe Palpebral Ptosis) or systemic illnesses that may affect the visual system and alter the results (such as Severe Cardiopathies, Diabetes Mellitus, oncological diseases, systemic tissue disorders, chronic infectious diseases or conditions after organ or tissue transplantation).
* Subjects with neurodegenerative or neural diseases other than the study itself, such as Alzheimer's disease, Devic's disease, Huntington's disease, Creutzfeldt-Jakob disease, epilepsy, ataxia, multiple sclerosis or amyotrophic lateral sclerosis.
* Subjects taking medication that may alter any visual ability such as anxiolytics, antidepressants, sleeping pills.
* Subjects with problems in understanding and following the tests.
* Patients who have been previously treated under a vision therapy program.

Where this trial is running

Valencia

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Parkinson Disease, Parkinson's Disease, Vision, Ocular Motility Disorders, Perceptual Disorders

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.